Literature DB >> 31900358

NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.

Rachael H Earls1, Kelly B Menees1, Jaegwon Chung1, Claire-Anne Gutekunst2, Hyun Joon Lee3,4, Manuel G Hazim2, Balázs Rada5, Levi B Wood6,7, Jae-Kyung Lee8.   

Abstract

The pathological hallmark of synucleinopathies, including Lewy body dementia and Parkinson's disease (PD), is the presence of Lewy bodies, which are primarily composed of intracellular inclusions of misfolded α-synuclein (α-syn) among other proteins. α-Syn is found in extracellular biological fluids in PD patients and has been implicated in modulating immune responses in the central nervous system (CNS) and the periphery. Natural killer (NK) cells are innate effector lymphocytes that are present in the CNS in homeostatic and pathological conditions. NK cell numbers are increased in the blood of PD patients and their activity is associated with disease severity; however, the role of NK cells in the context of α-synucleinopathies has never been explored. Here, we show that human NK cells can efficiently internalize and degrade α-syn aggregates via the endosomal/lysosomal pathway. We demonstrate that α-syn aggregates attenuate NK cell cytotoxicity in a dose-dependent manner and decrease the release of the proinflammatory cytokine, IFN-γ. To address the role of NK cells in PD pathogenesis, NK cell function was investigated in a preformed fibril α-syn-induced mouse PD model. Our studies demonstrate that in vivo depletion of NK cells in a preclinical mouse PD model resulted in exacerbated motor deficits and increased phosphorylated α-syn deposits. Collectively, our data provide a role of NK cells in modulating synuclein pathology and motor symptoms in a preclinical mouse model of PD, which could be developed into a therapeutic for PD and other synucleinopathies.

Entities:  

Keywords:  Lewy bodies; Parkinson’s disease; natural killer cell; synucleinopathies; α-synuclein

Mesh:

Substances:

Year:  2020        PMID: 31900358      PMCID: PMC6983411          DOI: 10.1073/pnas.1909110117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  76 in total

1.  A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

Authors:  B I Giasson; I V Murray; J Q Trojanowski; V M Lee
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

2.  FimH can directly activate human and murine natural killer cells via TLR4.

Authors:  M Firoz Mian; Nicole M Lauzon; David W Andrews; Brian D Lichty; Ali A Ashkar
Journal:  Mol Ther       Date:  2010-05-04       Impact factor: 11.454

3.  Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Martin D Curran; Mark J Gibson; Jennifer A Court; Michael G Schlossmacher; David Allsop
Journal:  FASEB J       Date:  2006-03       Impact factor: 5.191

4.  Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

5.  Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Authors:  Sabrina Genßler; Michael C Burger; Congcong Zhang; Sarah Oelsner; Iris Mildenberger; Marlies Wagner; Joachim P Steinbach; Winfried S Wels
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

6.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia.

Authors:  Changyoun Kim; Dong-Hwan Ho; Ji-Eun Suk; Sungyong You; Sarah Michael; Junghee Kang; Sung Joong Lee; Eliezer Masliah; Daehee Hwang; He-Jin Lee; Seung-Jae Lee
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  NK cells play a critical protective role in host defense against acute extracellular Staphylococcus aureus bacterial infection in the lung.

Authors:  Cherrie-Lee Small; Sarah McCormick; Navkiran Gill; Kapilan Kugathasan; Michael Santosuosso; Nickett Donaldson; David E Heinrichs; Ali Ashkar; Zhou Xing
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

8.  Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.

Authors:  Dawn Béraud; Hannah A Hathaway; Jordan Trecki; Sergey Chasovskikh; Delinda A Johnson; Jeffrey A Johnson; Howard J Federoff; Mika Shimoji; Timothy R Mhyre; Kathleen A Maguire-Zeiss
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-10       Impact factor: 4.147

9.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice.

Authors:  Kelvin C Luk; Victoria M Kehm; Bin Zhang; Patrick O'Brien; John Q Trojanowski; Virginia M Y Lee
Journal:  J Exp Med       Date:  2012-04-16       Impact factor: 14.307

10.  Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia.

Authors:  Lisa Fellner; Regina Irschick; Kathrin Schanda; Markus Reindl; Lars Klimaschewski; Werner Poewe; Gregor K Wenning; Nadia Stefanova
Journal:  Glia       Date:  2012-10-25       Impact factor: 7.452

View more
  24 in total

Review 1.  Interaction Between Innate Lymphoid Cells and the Nervous System.

Authors:  Yuanyue Zhang; Rachel Grazda; Qi Yang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  Innate and Innate-like Effector Lymphocytes in Health and Disease.

Authors:  Luc Van Kaer; J Luke Postoak; Wenqiang Song; Lan Wu
Journal:  J Immunol       Date:  2022-07-15       Impact factor: 5.426

Review 3.  Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies.

Authors:  Miriam Højholt Terkelsen; Ida H Klaestrup; Victor Hvingelby; Johanne Lauritsen; Nicola Pavese; Marina Romero-Ramos
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  New Insights and Implications of Natural Killer Cells in Parkinson's Disease.

Authors:  Kelly B Menees; Jae-Kyung Lee
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  Pathological Role of Natural Killer Cells in Parkinson's Disease: A Systematic Review.

Authors:  Le Zhang; Yingshuang Zhang; Dongsheng Fan
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

6.  DNA methylation-based surrogates of plasma proteins are associated with Parkinson's disease risk.

Authors:  Katherine A Fu; Kimberly C Paul; Ake T Lu; Steve Horvath; Adrienne M Keener; Yvette Bordelon; Jeff M Bronstein; Beate Ritz
Journal:  J Neurol Sci       Date:  2021-11-03       Impact factor: 4.553

7.  T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of α-Synuclein Fibrils.

Authors:  Sonia George; Trevor Tyson; Nolwen L Rey; Rachael Sheridan; Wouter Peelaerts; Katelyn Becker; Emily Schulz; Lindsay Meyerdirk; Amanda R Burmeister; Christian U von Linstow; Jennifer A Steiner; Martha L Escobar Galvis; Jiyan Ma; J Andrew Pospisilik; Viviane Labrie; Lena Brundin; Patrik Brundin
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

8.  MRI Guided Focused Ultrasound-Mediated Delivery of Therapeutic Cells to the Brain: A Review of the State-of-the-Art Methodology and Future Applications.

Authors:  Nabid Ahmed; Dheeraj Gandhi; Elias R Melhem; Victor Frenkel
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.086

Review 9.  Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.

Authors:  Somin Kwon; Michiyo Iba; Changyoun Kim; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

Review 10.  Modeling Parkinson's Disease With the Alpha-Synuclein Protein.

Authors:  Mónica Gómez-Benito; Noelia Granado; Patricia García-Sanz; Anne Michel; Mireille Dumoulin; Rosario Moratalla
Journal:  Front Pharmacol       Date:  2020-04-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.